Reprogramming the gut–brain axis in neurodegeneration: comparative microbiome, metabolite, immunometabolic, polyphenol, probiotic, and epigenetic mechanisms in Alzheimer’s and Parkinson’s diseases
- 1College of Post and Telecommunication of Wuhan Institute of Technology, College of Chemical and Materials Engineering, Wuhan, Hubei, China
- 2Department of Gastroenterology, Xiangshan Hospital of Traditional Chinese Medicine Medical and Health Group, Ningbo, Zhejiang, China
- 3Department of Gastroenterology, Hangzhou TCM Hospital, Hangzhou, China
Abstract
The gut–brain axis has emerged as a central mechanistic framework linking dietary bioactives, microbial ecology, and neurodegenerative disease progression. Similar microbiome-related mechanisms have also been implicated in colorectal cancer, suggesting potential shared links between microbial dysbiosis, inflammation, and disease progression. This study synthesizes preclinical evidence examining how polyphenols, polyphenol-derived compounds, and advanced delivery systems, including nanoparticles and synbiotics, modulate Alzheimer’s disease (AD) and Parkinson’s disease (PD) through microbiome-dependent mechanisms. Evidence from transgenic mice, toxin-induced rodent models, and Drosophila systems was compared across microbiome alterations, microbial metabolites, signaling pathways, epigenetic regulation, and functional outcomes. Across AD and PD models, dietary bioactives consistently promoted restoration of gut microbial homeostasis, characterized by enrichment of beneficial taxa and reduction of dysbiosis-associated microorganisms. These changes were accompanied by alterations in microbial metabolites, particularly short-chain fatty acids (SCFAs), tryptophan-derived metabolites, and lipid-associated signaling molecules. These metabolites provide functional links between microbial ecology and CNS physiology and may regulate epigenetic processes, including histone acetylation, DNA methylation, chromatin remodeling, and non-coding RNA activity. Despite substantial upstream convergence, downstream effects showed disease-specific patterns. In AD models, microbiome modulation predominantly influenced metabolic, amyloidogenic, and neurotrophic pathways, including AKT/GSK3β, NRF2, NF-κB, and BDNF-associated signaling, contributing to reduced amyloid-β deposition, attenuated tau pathology, and improved cognitive outcomes. In PD models, greater emphasis was placed on inflammatory, oxidative, and mitochondrial pathways involving SIRT1/NRF2, TLR4/MyD88/NF-κB, inflammasome signaling, and neuronal survival mechanisms, resulting in reduced neuroinflammation and preservation of dopaminergic neurons and motor function. Epigenetic regulation represents an additional convergence layer through which microbial metabolites and polyphenols may influence inflammatory, metabolic, mitochondrial, and neuronal gene programs in both disorders. Nanoparticle-based delivery systems enhanced bioavailability, tissue targeting, and microbiome-related effects, whereas synbiotic strategies reinforced microbial and metabolic homeostasis. Collectively, these findings support a microbiome–metabolite–epigenome–brain framework in which dietary bioactives modulate neurodegeneration through interconnected microbial, metabolic, immune, redox, mitochondrial, and epigenetic pathways. This framework provides a mechanistic basis for developing disease-tailored and precision-oriented gut–brain interventions for AD and PD.
Related
- Microbiome-mitochondria crosstalk in neuro-oncology: molecular mechanisms, immunometabolic reprogramming, and therapeutic opportunities
- Gut microbial metabolism in aging: from metabolite production to organ-specific immunometabolic effects
- Immunometabolic reprogramming of macrophages by gut microbiota-derived cadaverine controls colon inflammation
- Gut microbiota-ferroptosis signaling as a putative feed-forward amplifier of pulmonary immunometabolic reprogramming in acute respiratory distress syndrome: actionable therapeutic targets
- 3-(3-Hydroxyphenyl)propionic Acid-Induced Trained Immunity in Bone Marrow-Derived Macrophages Is Associated with Glutamate-Related Immunometabolic Reprogramming
BibTeX
@article{cheng2026reprogramming,
title = {{Reprogramming the gut–brain axis in neurodegeneration: comparative microbiome, metabolite, immunometabolic, polyphenol, probiotic, and epigenetic mechanisms in Alzheimer’s and Parkinson’s diseases}},
author = {Yu Jie Cheng and Mei Ping Tao and Kexin Qian and Wei Ye},
journal = {Frontiers in Aging Neuroscience},
year = {2026},
month = oct,
doi = {10.3389/fnagi.2026.1865514},
url = {https://doi.org/10.3389/fnagi.2026.1865514},
note = {CC BY},
}
RIS
TY - JOUR
TI - Reprogramming the gut–brain axis in neurodegeneration: comparative microbiome, metabolite, immunometabolic, polyphenol, probiotic, and epigenetic mechanisms in Alzheimer’s and Parkinson’s diseases
AU - Yu Jie Cheng
AU - Mei Ping Tao
AU - Kexin Qian
AU - Wei Ye
PY - 2026
DA - 2026/10/23
JO - Frontiers in Aging Neuroscience
DO - 10.3389/fnagi.2026.1865514
UR - https://doi.org/10.3389/fnagi.2026.1865514
AB - The gut–brain axis has emerged as a central mechanistic framework linking dietary bioactives, microbial ecology, and neurodegenerative disease progression. Similar microbiome-related mechanisms have also been implicated in colorectal cancer, suggesting potential shared links between microbial dysbiosis, inflammation, and disease progression. This study synthesizes preclinical evidence examining how polyphenols, polyphenol-derived compounds, and advanced delivery systems, including nanoparticles and synbiotics, modulate Alzheimer’s disease (AD) and Parkinson’s disease (PD) through microbiome-dependent mechanisms. Evidence from transgenic mice, toxin-induced rodent models, and Drosophila systems was compared across microbiome alterations, microbial metabolites, signaling pathways, epigenetic regulation, and functional outcomes. Across AD and PD models, dietary bioactives consistently promoted restoration of gut microbial homeostasis, characterized by enrichment of beneficial taxa and reduction of dysbiosis-associated microorganisms. These changes were accompanied by alterations in microbial metabolites, particularly short-chain fatty acids (SCFAs), tryptophan-derived metabolites, and lipid-associated signaling molecules. These metabolites provide functional links between microbial ecology and CNS physiology and may regulate epigenetic processes, including histone acetylation, DNA methylation, chromatin remodeling, and non-coding RNA activity. Despite substantial upstream convergence, downstream effects showed disease-specific patterns. In AD models, microbiome modulation predominantly influenced metabolic, amyloidogenic, and neurotrophic pathways, including AKT/GSK3β, NRF2, NF-κB, and BDNF-associated signaling, contributing to reduced amyloid-β deposition, attenuated tau pathology, and improved cognitive outcomes. In PD models, greater emphasis was placed on inflammatory, oxidative, and mitochondrial pathways involving SIRT1/NRF2, TLR4/MyD88/NF-κB, inflammasome signaling, and neuronal survival mechanisms, resulting in reduced neuroinflammation and preservation of dopaminergic neurons and motor function. Epigenetic regulation represents an additional convergence layer through which microbial metabolites and polyphenols may influence inflammatory, metabolic, mitochondrial, and neuronal gene programs in both disorders. Nanoparticle-based delivery systems enhanced bioavailability, tissue targeting, and microbiome-related effects, whereas synbiotic strategies reinforced microbial and metabolic homeostasis. Collectively, these findings support a microbiome–metabolite–epigenome–brain framework in which dietary bioactives modulate neurodegeneration through interconnected microbial, metabolic, immune, redox, mitochondrial, and epigenetic pathways. This framework provides a mechanistic basis for developing disease-tailored and precision-oriented gut–brain interventions for AD and PD.
SN - 1663-4365
ER -